Table 13Key outcomes of studies assessing SRIs

Author, Year, Country
Groups, N Enrollment/N Final
Study Quality
Mean Age, Years ± SDMean IQ ± SDOutcome Measure/Baseline Scores, Mean ± SDOutcome Measure/Post-Treatment Scores, Mean ± SD
Quality Considerations
Remington et al.,50 2001
Canada

G1: Clomipramine
G2: Haloperidol
G3: Placebo
Overall N: 37/36

Quality: Fair
Overall: 16.3 (SD NR)NRCARS
Overall: 41.8 ± 7.1
CARS:
G1: 37.8 ± 8.7
G2: 36.7 ± 6.1
G3: 39.4 ± 7.0
p<0.05, G2 vs. baseline

ABC reported only graphically

Quality considerations: participants not clearly characterized (no cognitive or developmental measures); treatment adherence not reported; outcomes not coded by masked assessors
McDougle et al.,68 1998
United States

G1: Sertraline, n = 42/37
G1a: AD
G1b: AS
G1c: PDD NOS

Quality: Poor
26.1 ± 5.860.5 ± 22.7 (28 with intellectual disability)Y-BOCS, total score:
G1a: 16.5 ± 6.7
G1b: 25.7 ±4.1
G1c: 18.2 ± 4.8

Vineland maladaptive behavior:
G1a: 27.0 ± 9.4
G1b: 19.8 ± 8.6
G1c: 28.3 ± 10.8

SIB-Q:
G1a: 32.7 ± 16.5
G1b: 17.5 ± 7.7
G1c: 36.2 ± 16.4
Y-BOCS, total score:
G1a: 11.5 ± 5.8
G1b: 27.8 ± 5.3
G1c: 14.8 ± 5.7
p = 0.005, G1 vs. baseline

Vineland maladaptive behavior:
G1a: 13.8 ± 6.0
G1b: 20.2 ± 8.2
G1c: 19.5 ± 9.1
p = 0.0001, G1 vs. baseline

SIB-Q:
G1a: 15.5 ± 9.5
G1b: 18.8 ± 7.7
G1c: 20.2 ± 12.8
p = 0.0001, G1 vs. baseline

Quality considerations: no comparison group; treatment adherence not reported; outcomes not coded by masked assessors; differences in concomitant interventions not reported
Brodkin et al.,69 1997
United States

G1: Clomipramine, 35/33
G1a: Responders, n = 18
G1b: Nonresponders, n = 15

Quality: Poor
G1: 30.2 ± 7.0G1: 64.6 ± 27.2Y-BOCS, total score:
G1a: 18.7 ± 6.8
G1b: 17.9 ± 6.2

Y-BOCS, compulsion subscale:
G1a: 13.7 ± 3.3
G1b: 13.9 ± 2.5

Y-BOCS, obsession subscale:
G1a: 10 ± 6.8
G1b: 6.7 ± 6.2

Brown Aggression Scale:
G1a: 10.6 ± 7.4
G1b: 6.5 ± 4.1
Y-BOCS, total score:
G1a: 9.1 ± 3.0
G1b: 17.3 ± 7.8
p<0.001, G1 vs. baseline
p<0.001, G1a vs. G1b

Y-BOCS, compulsion subscale:
G1a: 6.9 ± 2.1
G1b: 12.5 ± 3.3
p<0.001, G1 vs. baseline p< 0.001, G1a vs. G1b

Y-BOCS, obsession subscale:
G1a: 4.4 ± 2.8
G1b: 8 ± 6.6
p<0.001, G1 vs. baseline
p<0.001, G1a vs. G1b

Brown Aggression Scale:
G1a: 3.7 ± 3.6
G1b: 6.4 ± 4.6
p<0.001, G1 vs. baseline
p<0.001, G1a vs. G1b

Quality considerations: no comparison group; treatment adherence not reported; outcomes not coded by masked assessors
McDougle et al.,52 1996
United States

G1: Fluvoxamine, 15/15
G2: Placebo, 15/15

Quality: Fair
G1: 30.1 ± 7.1
G2: 30.1 ± 8.4
G1: 82.5 ± 26.8
G2: 77.3 ± 33.1
Y-BOCS, total score:
G1: 21.4 ± 7.3
G2: 21.5 ± 6.8
Y-BOCS, total score:
G1: 13.7 ± 9.1
G2: 21.9 ± 6.7
p<.003, G1 vs. G2

Data for Vineland Maladaptive Behavior and Brown Aggression Scale were not reported, although statistically significant improvements were noted.

Quality considerations: randomization method not clearly described; treatment adherence not reported
Cook et al.,71 1992
United States

G1: Fluoxetine, 23/23

Quality: Poor
15.9 ± 6.2NR, 19 with intellectual disabilityCGI-S, total:
5.7 ± 0.8

CGI-S, compulsion:
5.5 ± 1.5
CGI-S, total:
4.9 ± 1.1
p<0.002, G1 vs. baseline

CGI-S, compulsion:
4.7 ±1.6
p<0.005, G1 vs. baseline

Quality considerations: no comparison group; inclusion and exclusion criteria not clearly stated; treatment adherence not reported; outcomes not coded by masked assessors

ABC = Aberrant Behavior Checklist; ABC-I = Aberrant Behavior Checklist-Community Rating Scale-Irritability; CARS = Childhood Autism Rating Scale; CGI-S = Clinical Global Impression-Severity; G = group; n = number; NR = not reported; PDD-NOS = pervasive developmental disorder-not otherwise specified; SD = standard deviation; SIB-Q = Self-Injurious Behavior Questionnaire; SRIs = serotonin reuptake inhibitors; Y-BOCS = Yale-Brown Obsessive Compulsive Scale

From: Results

Cover of Interventions for Adolescents and Young Adults With Autism Spectrum Disorders
Interventions for Adolescents and Young Adults With Autism Spectrum Disorders [Internet].
Comparative Effectiveness Reviews, No. 65.
Lounds Taylor J, Dove D, Veenstra-VanderWeele J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.